At the heart of Resyca’s soft mist technology is a 1 × 1 mm silicon micro-pore nozzle chip, fabricated using advanced semiconductor processes.
The chip features an array of micropores, typically 1–5 μm in diameter, producing liquid jets that break into droplets via Rayleigh theory, with droplet size roughly twice the pore diameter. This ensures predictable aerosol characteristics with a narrow distribution.
Spray duration, droplet size, and plume geometry are precisely tuneable, enabling applications from pulmonary delivery to nose-to-brain targeting. The technology offers scalability, reproducibility, and cost-efficiency, suitable for both specialised therapies and high-volume pharmaceutical products.
– Protecting your Biologics From Fill to Patient
Resyca’s soft mist devices integrate the spray nozzle directly into the primary packaging, ensuring stability and sterility for delicate formulations.
Central to this system is a customised Stevanato Alba® EZ-fill® glass syringe, silicone-coated and optimised for biologics. The precision silicon nozzle and one-way valve ensure accurate dosing and container closure integrity throughout shelf life and in-use.
The primary packaging minimises residual volume while remaining compatible with multiple nozzle configurations. Available in 0.5 mL and 1.0 mL formats, syringes are manufactured and EtO-sterilised on validated Resyca lines. Ready-to-use Nest & Tub configurations streamline fill–finish operations for reliable, efficient production.
Delivering biologics via inhalation presents unique challenges – sensitivity to aerosolisation stress, storage stability, and efficient targeting.
Conventional devices often expose formulations to high shear forces, causing aggregation, degradation, or loss of therapeutic activity. Resyca’s soft mist nozzle overcomes these limitations with gentle aerosolisation that preserves molecular integrity.
This makes the technology ideally suited for advanced biologics, including gene therapies and vaccines, and opens new opportunities for both nasal and pulmonary delivery.
Efficient drug delivery depends on patient inhalation technique.
Resyca’s soft mist inhaler (SMI) platform integrates a customisable flow resistance to naturally guide the patient to a long and deep inhalations, thereby improving deposition consistency, lung dose, and reduced patient to-patient variability.
Insufficient inspiratory flow resistance often leads to shorter, more forceful inhalations that require extensive device training. Resyca’s inspiratory flow-guidance makes inhalation intuitive, reliable, and effective across patient populations.
